Cadila Healthcare receives final approval for Pyridostigmine Bromide Tablets
From US FDA
Cadila Healthcare announced that it has received the final approval from the US FDA to market Pyridostigmine Bromide Tablets USP, 60 mg. The estimated sales in 2015 for Pyridostigmine Bromide Tablets USP which is used in the treatment of various neurological disorders is USD 27.9 million as per IMS.Powered by Capital Market - Live News